NEW YORK (GenomeWeb News) – Houston-based startup Castle Biosciences has signed an option agreement to license a biomarker-based brain cancer test from the University of Texas MD Anderson Cancer Center.
 
The firm said that the test, which was developed and validated at MD Anderson in collaboration with other US institutions, could potentially predict a patient’s likelihood to respond to standard treatment based on the cancer’s genetic footprint. It said that it would provide more details on the test in the near future.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.